Top
Home Market Activity Get Quotes Quote
PRINT HELP

Medicenna Therapeutics Corp.

TSX Exchange | Dec 9, 2019, 12:51 PM EST | Real-time price

MDNA $ 1.70 RT
CHANGE
0.355 (26.394%)
VOLUME
264,885
Day Low: 1.39
Day High: 1.70
52 Week Low: 0.64
52 Week High: 2.38
Detailed Quote
Open: 1.40
High: 1.70
Beta: 2.4059
Listed Shares Out.1: 34,110,485
Total Shares (All Classes)2: 28,802,792
Prev. Close: 1.345
Low: 1.39
VWAP: 1.4953
Market Cap1: 57,987,825
Market Cap (All Classes)2*: 48,964,746
Dividend: N/A
Div. Frequency: N/A
P/E Ratio: N/A
EPS: -0.19
Yield: N/A
Ex-Div Date: N/A
P/B Ratio: 34.
Exchange: TSX

(1) Number based only on listed classes of shares.

(2) Number sourced from third party data provider. For the most up to date information, please refer to the company's financial documents.

*Market Capitalization is based on Total Shares Outstanding for all share classes for the company. Convertible bonds and employee stock options that would otherwise be included in the Diluted Shares amount included in a company's filings/financials are not included.

Description

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the po... More

News Headlines for Medicenna Therapeutics Corp.
Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit

PR Newswire , 7:30 AM EST December 09, 2019

Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit

Canada Newswire , 7:30 AM EST December 09, 2019

Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting

Canada Newswire , 7:30 AM EST November 25, 2019

More News
Research
News Headlines for Medicenna Therapeutics Corp.
Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit

PR Newswire , 7:30 AM EST December 09, 2019

Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit

Canada Newswire , 7:30 AM EST December 09, 2019

Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting

Canada Newswire , 7:30 AM EST November 25, 2019

More News
Last 25 Trades
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia, Fundamentals by Morningstar. See the QuoteMedia Terms of Use.